neuroimmunology

7 · 20 / page

Ask MedXY AI

Latest news

Tag

Allergy & Immunologyclinical trialDisease-Modifying Therapy

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study

By MedXY|Apr 22, 2026

Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c

Age at Onset and Clinical Trajectory in AQP4-IgG NMOSD: Decoupling Relapse Risk from Disability Accrual

Clinical UpdatesDisease Progressionneuroimmunology

neuroimmunology

Latest news

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study

Age at Onset and Clinical Trajectory in AQP4-IgG NMOSD: Decoupling Relapse Risk from Disability Accrual

Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention

NEOS2 Score: A Precision Tool for Predicting Treatment Response and Three-Year Functional Recovery in Anti-NMDAR Encephalitis

Refining Prognosis in Anti-NMDAR Encephalitis: The NEOS2 Score Predicts Short- and Long-Term Recovery

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy